Use of 5-α reductase inhibitors for benign prostatic hyperplasia (BPH) does not significantly increase the risk of hip fracture, researchers concluded in The Journal of the American Medical Association (2008;300:1660-1664).

They compared 7,076 men aged 45 years and older who had a hip fracture and a like number of men without a hip fracture.

A prior diagnosis of BPH was identified in 36% and 35% of men with and without a hip fracture, respectively.

Topics:

BPH Drugs Not a Hip Fracture Risk